
Sales growth of ALK’s allergy tablets alongside the 2022 guidance will be center stage tomorrow, when the allergy company publicizes its full-year financial report.
The company has delivered nice organic growth rates in recent years, with 2019 coming to 11 percent and 2020 bringing 8 percent. The newly ended year 2021 is also expected to have landed double-digit organic growth.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app